Results 71 to 80 of about 472,035 (296)
Time to initiation of antiresorptive agents in multiple myeloma to reduce skeletal related events
Frontiers in HematologyPurposeCurrent treatment guidelines strongly support the use of antiresorptive therapy in patients with newly diagnosed multiple myeloma (NDMM) with the goal of preventing skeletal related events (SRE). Despite these concrete, data-driven recommendations,
Amman Bhasin +11 more
doaj +1 more source
FEBS Open Bio, EarlyView.The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley +1 more source
Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system [PDF]
, 2016 Nazia Rashid,1 Han A Koh,2 Hilda C Baca,3 Kathy J Lin,1 Susan E Malecha,4 Anthony Masaquel5 1Drug Information Services, Kaiser Permanente, Downey, 2Southern California Permanente Medical Group, Kaiser Permanente, Bellflower, 3Pharmacy Analytical Services,
Koh HA +5 more
core
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events. [PDF]
, 2014 35 Background: In a randomized controlled trial of men with castration-resistant prostate cancer (CRPC) and bone metastases, denosumab was superior to zoledronic acid (ZA) for reducing skeletal-related events (SRE, defined as pathological fracture ...
Arun Balakumaran +7 more
core +1 more source
Skeletal system of the prostate, bladder and kidney tumors, and biphosphonate treatment
Urology Research and Practice, 2019 Genitourinary system tumors are the most common tumors with bone metastases. Bone metastases are observed in advanced prostate, bladder and kidney cancers.
Ferhat Ateş, Kadir Vehbi Baykal
doaj +2 more sources
Targeted Treatments of Bone Metastases in Patients with Lung Cancer
Frontiers in Oncology, 2014 Until now approximately 30-40% of patients with advanced lung cancer develop bone metastases, but as the newer therapies are extending survival, the chance of developing bone metastases increases.Bone metastases cause skeletal-related events (SREs) such ...
Vera eHirsh
doaj +1 more source
BMC Cancer, 2020 Background In patients with metastatic cancer, the bone is the third-most common site of involvement. Radiation to painful bone metastases results in high rates of pain control and is an integral part of bone metastases management.
Daniel B. Rosen +8 more
doaj +1 more source
Cracking the Code: Genotype–Phenotype Correlation Models in Sarcoglycanopathies
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Sarcoglycanopathies are among the most severe limb‐girdle muscular dystrophies (LGMD), though milder presentations have been described. These diseases are primarily caused by missense variants, but the limited predictability of their effect on protein maturation, complex formation, and transport has hindered reliable genotype ...
Leonela Luce +72 more
wiley +1 more source
Skeletal-Related Events in Patients with Metastatic Renal Cell Carcinoma: A Systematic Review
Kidney Cancer, 2020 About one-third of advanced renal cell carcinoma (RCC) patients have bone metastases, which subsequently leads to the development of skeletal-related events (SREs), broadly defined to include surgery and radiation to bone, bone pain, pathological ...
Albert Jang +4 more
doaj +1 more source